Absci, a Vancouver-based drug development startup, has initiated its first Phase I clinical trial for ABS-101, a therapy developed entirely using generative AI to address irritable bowel disease. This milestone is significant as no fully AI-developed drugs have secured regulatory approval yet. The Phase I trial aims to assess the safety and tolerability of ABS-101 in healthy volunteers, marking a critical step in integrating AI into pharmaceutical development. The trial will enroll around 40 participants and will evaluate pharmacokinetics and immunogenicity as secondary endpoints, with interim results anticipated shortly.
This is a very big milestone for the company, we're excited to become a clinical-stage biotech company; it's exciting from an AI drug discovery standpoint.
The Phase 1 randomized, double-blind, placebo-controlled study of ABS-101 will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers.
Collection
[
|
...
]